Placebo for AMG 334, Erenumab clinical trials

A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Erenumab in Children (6 to < 12 Years) and Adolescents (12 to < 18 Years) With Chronic Migraine (OASIS PEDIATRIC [CM])

This study is testing a new medicine, Erenumab, for children and teenagers aged 6 to 17 who get chronic migraines. It wants to see if the medicine can reduce how often and how severe their migraines are, compared to a dummy medicine.